Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like How Pfizer Made Most of Its $52.8 Billion Last Year April 17, 2017 The World's Richest Doctor's New Cancer Vaccine and NantKwest's Science February 22, 2017 Providence Medical Technology Announces Publication Of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion July 9, 2017
Providence Medical Technology Announces Publication Of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion July 9, 2017
